PWPS
IKT icon

Pinnacle Wealth Planning Services’s Inhibikase Therapeutics IKT Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11K Hold
5,400
– – ﹤0.01% 2030
2026
Q1 		$9.07K Hold
5,400
– – ﹤0.01% 2041
2025
Q4 		$11.1K Buy
+5,400
New +$8.59K ﹤0.01% 1970

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pinnacle Wealth Planning Services's IKT Position: Q2 2026 in Review

Pinnacle Wealth Planning Services held its Inhibikase Therapeutics (IKT) position steady in Q2 2026 at 5,400 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #2030.

Pinnacle Wealth Planning Services first reported a position in IKT in Q4 2025 and has held it in 3 quarters since. The position peaked at $11.1K in Q4 2025. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Pinnacle Wealth Planning Services held 5,400 shares of Inhibikase Therapeutics worth $11K as of Q2 2026.
  • Pinnacle Wealth Planning Services left its Inhibikase Therapeutics share count unchanged in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #2030 holding.
  • Pinnacle Wealth Planning Services first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pinnacle Wealth Planning Services's Inhibikase Therapeutics position peaked at $11.1K in Q4 2025.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.